Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EFFECT-neo: A Prospective, Open-label, Multicenter Phase III Study to Evaluate Efficacy and Safety of Pembrolizumab Combined With Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC

NCT06102395 is registered in ClinicalTrials.gov with Beijing Tongren Hospital as lead sponsor.

NCT NCT06102395
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06102395 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EFFECT-neo: A Prospective, Open-label, Multicenter Phase III Study to Evaluate Efficacy and Safety of Pembrolizumab Combined With Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC
Lead sponsor
Beijing Tongren Hospital
Phase
Phase 3
Overall status
Recruiting
Start date
May 1, 2023
Completion date
April 30, 2030
Enrollment
272 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck squamous cell carcinoma, neoadjuvant therapy, pembrolizumab